Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 737 • 2015 ACR/ARHP Annual Meeting
A Paper Patient-Based Flare Study in SLE
Joanna Sturgess¹, Elizabeth Allan¹, David A. Isenberg², Cynthia Aranow³, Martin Aringer⁴, Anca Askanase⁵, Sang-Cheol Bae⁶, Sasha R Bernatsky⁷, Ian N. Bruce⁸, Jill P. Buyon⁹, Ricard Cervera¹⁰, Ann Clarke¹¹, Mary Anne Dooley¹², Paul R. Fortin¹³, Ian Giles², Ellen M. Ginzler¹⁴, Dafna Gladman¹⁵, Caroline Gordon¹⁶, Bridget Griffiths¹⁷, John G. Hanly¹⁸, Murat Inanc¹⁹, Søren Jacobsen²⁰, Diane L. Kamen²¹, Munther Khamashta²², Peter Lanyon²³, S. Sam Lim²⁴, Susan Manzi²⁵, Marta Mosca²⁶, Ola Nived²⁷, Christine A. Peschken²⁸, Michelle Petri²⁹, Kenneth C. Kalunian³⁰, Anisur Rahman³¹, Rosalind Ramsey-Goldman³², Guillermo Ruiz-Irastorza³³, Jorge Sánchez-Guerrero³⁴, Matteus Schneider³⁵, Kristján Steinsson³⁶, Gunnar K. Sturfelt³⁷, Murray Urowitz^38,39, Ronald F. van Vollenhoven⁴⁰, Carlos Vasconcelos⁴¹, Daniel J Wallace⁴², Asad Zoma⁴³, Joan T. Merrill⁴⁴, Eric Morand⁴⁵, Sharon Chambers⁴⁶, Nathalie Costedoat-Chalumeau⁴⁷ and Sara Croca², ¹Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom, ²Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ³Feinstein Institute for Medical Research, Mahasset, NY, ⁴Rheumatology, Universitatsklinikum, Dresden, Germany, ⁵Columbia University College of Physicians & Surgeons, New York, NY, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁷Division of Rheumatolog, McGill Unversity Health Cener, Montreal, QC, Canada, ⁸Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ¹⁰Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain, ¹¹Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, ¹²UNC Kidney Centre, Chapel Hill, NC, ¹³Université Laval, CHU de Québec, Québec, QC, Canada, ¹⁴Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶Rheumatology (East Wing), Medical School, Birmingham, United Kingdom, ¹⁷Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁸Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ¹⁹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²⁰Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ²¹Medicine, Medical University of South Carolina, Charleston, SC, ²²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ²³Rheumatology, Queens Medical Centre Nottingham, Nottingham, United Kingdom, ²⁴Emory University School of Medicine, Atlanta, GA, ²⁵Rheumatology, Allegheny Health Network, Pittsburgh, PA, ²⁶University of Pisa, Pisa, Italy, ²⁷Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁸Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ²⁹Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ³⁰Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³¹Academic Centre for Rheumatology, University College London, London, United Kingdom, ³²Northwestern University Feinberg School of Medicine, Chicago, IL, ³³Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ³⁴Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada, ³⁵MNR-Klinik, Heinrich-Heine-Univ Dusseldorf, Dusseldorf, Germany, ³⁶Rheumatology, Univ. Hospital, Reykjavik, Iceland, ³⁷Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ³⁸University of Toronto, Toronto, ON, Canada, ³⁹Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴⁰Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴¹Medicina Interna, Unidade de Imunologia Clínica - Hospital Santo António, Oporto, Portugal, ⁴²Cedars-Sinai Medical Center, West Hollywood, CA, ⁴³Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ⁴⁴Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴⁵Medicine, Monash University, Clayton, Australia, ⁴⁶TrinCay Medical Services, Camana Bay, Cayman Islands, ⁴⁷Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France
ACR Abstract – A Paper Patient-Based Flare Study in Systemic Lupus Erythematosus (SLE) Isenberg D, Sturgess J, Allan E, Aranow C, Aringer M, Askanase A,…
Abstract Number: 747 • 2015 ACR/ARHP Annual Meeting
Depletion of Serum Soluble CD40L Characterizes the Association Between Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura: Longitudinal, Single-Center Study
Javier Merayo-Chalico¹, Ana Barrera-Vargas², Jorge Alcocer-Varela² and Diana Gómez-Martín², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher incidence of thrombotic thrombocytopenic purpura (TTP). Differentiating TTP from SLE activity may represent a challenge…
Abstract Number: 780 • 2015 ACR/ARHP Annual Meeting
Long-Term Prognosis and Factors Associated with Damage Accrual in Japanese Patients with Systemic Lupus Erythematosus
Yoko Wada¹, Hisashi Hasegawa², Takeshi Kuroda³, Masaaki Nakano⁴ and Ichiei Narita¹, ¹Department of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata City General Hospital, Niigata, Japan, ³Health Administration Center, Niigata University, Niigata, Japan, ⁴Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by fluctuating disease activity over periods of years. The estimated 5-year survival rate of…
Abstract Number: 1107 • 2015 ACR/ARHP Annual Meeting
Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark^1,2, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity and production of autoantibodies. Treatment of patients with moderate-to-severe SLE with epratuzumab, a humanized…
Abstract Number: 2935 • 2015 ACR/ARHP Annual Meeting
Disease Evolution in Late Onset and Early Onset Systemic Lupus Erythematosus (SLE)
Roa'a Al Johani¹, Dafna Gladman², Jiandong Su² and Murray Urowitz^2,3, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To compare clinical features, disease activity and outcome in late onset versus early onset SLE over 5 years of follow up. Methods: Patients with…
Abstract Number: 2953 • 2015 ACR/ARHP Annual Meeting
The Emergency Room and SLE: What Characteristics Are Associated with Increased Emergency Room Utilization in Lupus Patients?
Kimberly Trotter¹, Kichul Ko¹, Gabrielle Liu¹ and Tammy Utset², ¹Medicine, University of Chicago, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose: There is sparse data examining the characteristics of SLE patients who frequent the emergency room (ER). Data suggest that lupus patients with certain sociodemographic…
Abstract Number: 3218 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
William Stohl¹, Andreas Schwarting², Masato Okada³, Morton Scheinberg⁴, Andrea Doria⁵, Anne Hammer⁶, Christi Kleoudis⁷, Damon Bass⁸, James Groark⁹, Norma Lynn Fox¹⁰, David Roth¹¹ and David Gordon¹¹, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²ACURA Kliniken, Bad Kreuznach, Germany, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, ⁵Division of Rheumatology, University of Padova, Padova, Italy, ⁶GlaxoSmithKline, Research Triangle Park, NC, ⁷Parexel, Durham, NC, ⁸Immuno-Inflammation, GlaxoSmithKline, King of Prussia, PA, ⁹GlaxoSmithKline, Philadelphia, NC, ¹⁰GlaxoSmithKline, Washington, MD, ¹¹GlaxoSmithKline, Philadelphia, PA
Background/Purpose: To assess the efficacy and safety of belimumab (BEL) administered subcutaneously plus standard SLE care (SoC) in patients with active SLE.Methods: BLISS-SC (BEL112341; NCT01484496)…
Abstract Number: 697 • 2014 ACR/ARHP Annual Meeting
Venous and Arterial Thrombosis in SLE: Differences in Natural History
Katharine Hickman¹, Laurence S. Magder² and Michelle Petri³, ¹University College London, London, United Kingdom, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Thrombosis is increased in SLE due to disease activity and co-morbid factors including antiphospholipid antibodies. We separately investigated the natural history of venous vs.…
Abstract Number: 689 • 2014 ACR/ARHP Annual Meeting
Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE)
Khaled Alderaan¹, Vuk Sekicki², Laurence S. Magder³ and Michelle Petri⁴, ¹King Fahad Specilaist Hospital, Dammam, Saudi Arabia, ²Medicine, Saint Agnes Hospital, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cataract is the most common ocular damage in SLE. It is the second most frequent item in the SLICC/ACR Damage Index. Apart from cumulative…
Abstract Number: 2675 • 2014 ACR/ARHP Annual Meeting
The Selective Loss of SLAMF4⁺ CD8⁺ T Cells Contributes to the Decreased Cytotoxic Capacity Observed in Systemic Lupus Erythematosus
Katalin Kis-Toth¹, Denis Comte¹, Maria Karampetsou¹, Lakshmi Kannan² and George C. Tsokos¹, ¹Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ²Rheumtology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose Signaling lymphocytic activation molecule family member 4 (SLAMF4) engagement by its ligand SLAMF2 can mediate the cytotoxicity of CD8+ T cells and natural killer…
Abstract Number: 677 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Biological Activity of Intravenously or Subcutaneously Administered Tabalumab in Subjects with Rheumatoid Arthritis or Systemic Lupus Erythematosus
Jennifer Witcher¹, Ryan Hansen¹, Leijun Hu¹, David Radtke¹, James Voelker¹ and Juliet McColm², ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Windlesham, United Kingdom
Background/Purpose : B-cell activating factor (BAFF) promotes B-cell survival and maturation, and increased serum levels are associated with autoimmune disease and disease activity in systemic…
Abstract Number: 2674 • 2014 ACR/ARHP Annual Meeting
The Effect and Mechanisms of Icaritin on Regulating Foxp3/IL17a Expression in CD4⁺ T Cells from SLE
Jieyue Liao¹, Yu Liu², Ming Zhao³, hai Jing Wu⁴ and Qianjin Lu⁵, ¹Department of Dermatology, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Department of Dermatology, Second Xiangya Hospital, Central South University, shangcha, China, ³Department of Dermatology, Second Xiangya Hospital, Central South University, changsha, China, ⁴Department of Dermatology, Second Xiangya Hospital, Central South University, sahngsha, China, ⁵Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose : Systemic lupus erythematosus (SLE) is a female predominant autoimmune disease characterized by overproduction of autoantibodies. The pathogenesis of SLE is complex. Several studies…
Abstract Number: 2689 • 2014 ACR/ARHP Annual Meeting
The CUL4^CRBN E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Ikaros and Aiolos: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus
Peter H. Schafer¹, Ying Ye², Lei Wu³, Jolanta Kosek⁴, Zhihong Yang⁵, Liangang Liu⁵, Michael Thomas⁵, Maria Palmisano⁵ and Rajesh Chopra⁵, ¹Celgene Corporation, Celgene Corporation, Summit, NJ, ²86 Morris Avenue, Celgene Corporation, Summit, NJ, ³Department of Translational Development, Celgene Corporation, Summit, NJ, ⁴Translational Development, Celgene Corporation, Summit, NJ, ⁵Celgene Corporation, Summit, NJ
Background/Purpose: CC-220 is an immunomodulatory compound that binds to cereblon (CRBN), part of the CUL4CRBN E3 ubiquitin ligase complex, which has been shown to ubiquitinate…
Abstract Number: 2667 • 2014 ACR/ARHP Annual Meeting
First-Trimester Disease Activity Does Not Predict Pre-Eclampsia in SLE Pregnancy
Khaled Alderaan¹, Laurence S. Magder² and Michelle Petri³, ¹King Fahad Specilaist Hospital, Dammam, Saudi Arabia, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Preeclampsia complicates up to 35% of lupus pregnancies compared to 8% of general population pregnancies. SLE has up to a 3-fold increased rate of…
Abstract Number: 2635 • 2014 ACR/ARHP Annual Meeting
Noncalcified Plaque Progression in Systemic Lupus Erythematosus
Adnan Kiani¹, Armin Zadeh², Joao Lima², Laurence S. Magder³ and Michelle Petri⁴, ¹1830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Coronary atherosclerosis is a major cause of morbidity and mortality in SLE. New technology, computed tomoangiography (CTA) can measure non-calcified coronary plaque (NCP),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].